Wall Street Journal: Ovation in the News

February 21, 2023

“Researchers increasingly will use sequencing to discover treatments for complex conditions such as autoimmune, metabolic and neurological diseases,” explained Barry Wark, Ovation’s Co-founder and Chief Strategy Officer.

Ovation’s Curt Medeiros joined Barry for an interview with The Wall Street Journal about the potential to improve precision medicine by increasing access to genomic data and why low-cost sequencing will help us get there.

Read the article and learn more about advances in genomic sequencing.

Ovation Reaches 10,000 GLP-1 Clinicogenomic Patient Milestone, Now Available for Licensing

PrecisionLife and Ovation ink collaboration agreement to launch GLP-1 stratification LDT and consumer GLP-1 DNA test in H2 2026

PrecisionLife and Ovation identify first potential genetic biomarkers to quantitatively predict GLP-1 efficacy response

Ovation and DNAnexus Present at the 2nd Precision Medicine in IBD Summit

Learn about the transformative power of leveraging high-value multiomics data alongside an advanced..

Linking Genomic and Phenotypic Data to Better Understand the Patient Journey

In partnership with Datavant, we explore how researchers can overcome the challenges posed by..